TherapeuticsMD (NASDAQ:TXMD) Coverage Initiated at StockNews.com

Posted by Stacy Sanders on Aug 8th, 2024

StockNews.com initiated coverage on shares of TherapeuticsMD (NASDAQ:TXMD – Free Report) in a research report sent to investors on Monday. The brokerage issued a hold rating on the stock.

TherapeuticsMD Stock Down 3.5 %

Shares of TXMD opened at $1.67 on Monday. The business’s 50-day moving average is $1.83 and its two-hundred day moving average is $2.06. TherapeuticsMD has a fifty-two week low of $1.43 and a fifty-two week high of $4.20.

TherapeuticsMD (NASDAQ:TXMD – Get Free Report) last posted its earnings results on Friday, May 10th. The company reported ($0.07) EPS for the quarter. The company had revenue of $0.31 million during the quarter.

Institutional Trading of TherapeuticsMD

A hedge fund recently bought a new stake in TherapeuticsMD stock. Prosperity Consulting Group LLC acquired a new stake in TherapeuticsMD, Inc. (NASDAQ:TXMD – Free Report) during the 1st quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm acquired 24,500 shares of the company’s stock, valued at approximately $56,000. Prosperity Consulting Group LLC owned 0.21% of TherapeuticsMD at the end of the most recent quarter. Hedge funds and other institutional investors own 30.74% of the company’s stock.

TherapeuticsMD Company Profile

(Get Free Report)

TherapeuticsMD, Inc operates as a pharmaceutical royalty company in the United States. It has a license agreement with Mayne Pharma to commercialize the IMVEXXY, BIJUVA, and ANNOVERA prescription prenatal vitamin products sold under the BocaGreenMD and vitaMedMD brand names. The company sells its prescription pharmaceutical products and prenatal vitamin products through wholesale distributors and retail pharmacy distributors.